CD Patients on Originator Infliximab n=80	CD Patients on Biosimilar Infliximab n=44	P value
Age at diagnosis Median ( range)	13 years (8–16 )	12 years ( 3–16 )	n.s
Follow up period Median ( range)	33 months (1-71)	12 months (2–17	<0.05
Patients on Azathioprine	66/80 (83%)	32/44 (73%)	n.s
Patients with Anti-Infliximab antibodies	56/80 (70%)	34/44 (77%)	n.s
Patients with dose/frequency escalation of Infliximab	53/80 (66%)	27/44 (62%)	n.s
Patients in clinical remission	46/80 (58%)	27/44 (61%)	n.s
Patients with major infusion reaction	3/80 (4%)	1/44 (2%)	n.s